Details of the Drug

General Information of Drug (ID: DM1KS78)

Drug Name
Talazoparib
Synonyms Talazoparib (BMN 673); UNII-9QHX048FRV; 9QHX048FRV; Talazoparib [USAN:INN]; Talzenna; 4pjt; 2YQ
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Psoriatic arthritis FA21 Phase 3 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 380.4
Logarithm of the Partition Coefficient (xlogp) 2.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
Chemical Identifiers
Formula
C19H14F2N6O
IUPAC Name
(11S,12R)-7-fluoro-11-(4-fluorophenyl)-12-(2-methyl-1,2,4-triazol-3-yl)-2,3,10-triazatricyclo[7.3.1.05,13]trideca-1,5(13),6,8-tetraen-4-one
Canonical SMILES
CN1C(=NC=N1)[C@@H]2[C@H](NC3=CC(=CC4=C3C2=NNC4=O)F)C5=CC=C(C=C5)F
InChI
InChI=1S/C19H14F2N6O/c1-27-18(22-8-23-27)15-16(9-2-4-10(20)5-3-9)24-13-7-11(21)6-12-14(13)17(15)25-26-19(12)28/h2-8,15-16,24H,1H3,(H,26,28)/t15-,16-/m1/s1
InChIKey
HWGQMRYQVZSGDQ-HZPDHXFCSA-N
Cross-matching ID
PubChem CID
135565082
CAS Number
1207456-01-6
DrugBank ID
DB11760
TTD ID
D0GV8J
ACDINA ID
D01457
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Poly [ADP-ribose] polymerase (PARP) TTEBCY8 NOUNIPROTAC Inhibitor [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [3]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [4]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [4]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Drug Response [4]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [4]
Fumarate hydratase, mitochondrial (FH) OTEQWU6Q FUMH_HUMAN Drug Response [5]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Gene/Protein Processing [4]
Poly polymerase 2 (PARP2) OTYL81ZI PARP2_HUMAN Gene/Protein Processing [6]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Gene/Protein Processing [4]
Succinate dehydrogenase iron-sulfur subunit, mitochondrial (SDHB) OTRE1M1T SDHB_HUMAN Drug Response [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Talazoparib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
HKI-272 DM6QOVN Moderate Decreased clearance of Talazoparib due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [7]
Alpelisib DMEXMYK Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [7]
Coadministration of a Drug Treating the Disease Different from Talazoparib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Gilteritinib DMTI0ZO Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [7]
Ag-221 DMS0ZBI Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [8]
PF-04449913 DMSB068 Moderate Decreased clearance of Talazoparib due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [7]
Ingrezza DMVPLNC Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Ingrezza. Dystonic disorder [8A02] [7]
Berotralstat DMWA2DZ Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [7]
Capmatinib DMYCXKL Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [7]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Talazoparib and Siponimod. Multiple sclerosis [8A40] [8]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Talazoparib and Ocrelizumab. Multiple sclerosis [8A40] [9]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Talazoparib and Ozanimod. Multiple sclerosis [8A40] [10]
Rucaparib DM9PVX8 Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [7]
Darolutamide DMV7YFT Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [7]
Tedizolid DMG2SKR Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [7]
Elagolix DMB2C0E Moderate Decreased clearance of Talazoparib due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [7]
⏷ Show the Full List of 13 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Ferric oxide black E00522 16211978 Colorant
Hypromellose E00634 Not Available Coating agent
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Colcothar yellow E00436 518696 Colorant
Haematite red E00236 14833 Colorant
Ammonium hydroxide E00687 Not Available Alkalizing agent
Shellac E00695 Not Available Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Talazoparib 0.25 mg capsule 0.25 mg Capsule Oral
Talazoparib 1 mg capsule 1 mg Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8313).
3 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB11760)
4 BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile. J Biochem Mol Toxicol. 2019 May;33(5):e22286. doi: 10.1002/jbt.22286. Epub 2019 Jan 23.
5 Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair. Nat Genet. 2018 Aug;50(8):1086-1092. doi: 10.1038/s41588-018-0170-4. Epub 2018 Jul 16.
6 Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. J Med Chem. 2017 Feb 23;60(4):1262-1271. doi: 10.1021/acs.jmedchem.6b00990. Epub 2016 Dec 21.
7 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
8 Cerner Multum, Inc. "Australian Product Information.".
9 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
10 Cerner Multum, Inc. "UK Summary of Product Characteristics.".